Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Bone mineral density (BMD) declines when zoledronic acid (ZA) is administered. This case series describes the patterns of change in BMD when 1 or 2 doses of ZA are administered after denosumab. Methods: Twelve patients who received at least 2 doses of denosumab followed by at least 1 dose of ZA and who had a dual energy X-ray absorptiometry (DXA) scan at the end of denosumab and 1 year after the first dose of ZA were included. We excluded patients with bone cancer or conditions affecting bone metabolism, including hyperparathyroidism, rickets, osteogenesis imperfecta, rheumatologic disorders, fibrous dysplasia, Paget’s disease of bone, untreated hyperthyroidism, chronic kidney disease, liver cirrhosis, malabsorption, ongoing corticosteroid therapy, and aromatase inhibitor use. Results: There was a significant decline in BMD at the femoral neck within 1 year of the first ZA dose and a non-significant downward trend in the hip and lumbar spine. This trend was more severe in patients with osteoporosis at the time of drug transition. No increase in clinical vertebral fractures was observed. BMD seemed to stabilize in a smaller number of patients who received a second dose of ZA and had a DXA scan 1 year later. Conclusions: A single dose of ZA administered approximately 6 months after denosumab leads to some BMD loss, mostly within 1 year of ZA administration, particularly in patients with osteoporosis at the time of denosumab discontinuation.
Abstract
Background: Bone mineral density (BMD) declines when zoledronic acid (ZA) is administered. This case series describes the patterns of change in BMD when 1 or 2 doses of ZA are administered after denosumab. Methods: Twelve patients who received at least 2 doses of denosumab followed by at least 1 dose of ZA and who had a dual energy X-ray absorptiometry (DXA) scan at the end of denosumab and 1 year after the first dose of ZA were included. We excluded patients with bone cancer or conditions affecting bone metabolism, including hyperparathyroidism, rickets, osteogenesis imperfecta, rheumatologic disorders, fibrous dysplasia, Paget’s disease of bone, untreated hyperthyroidism, chronic kidney disease, liver cirrhosis, malabsorption, ongoing corticosteroid therapy, and aromatase inhibitor use. Results: There was a significant decline in BMD at the femoral neck within 1 year of the first ZA dose and a non-significant downward trend in the hip and lumbar spine. This trend was more severe in patients with osteoporosis at the time of drug transition. No increase in clinical vertebral fractures was observed. BMD seemed to stabilize in a smaller number of patients who received a second dose of ZA and had a DXA scan 1 year later. Conclusions: A single dose of ZA administered approximately 6 months after denosumab leads to some BMD loss, mostly within 1 year of ZA administration, particularly in patients with osteoporosis at the time of denosumab discontinuation.
참고문헌 (20)
- E M Lewiecki, "Denosumab for the Treatment of Osteoporosis and Cancer-Related Conditions", Clinical Pharmacology & Therapeutics, 91(1), pp.123~133 (2012), Springer Science and Business Media LLC[DOI]
- Steven R. Cummings, "Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis", New England Journal of Medicine, 361(8), pp.756~765 (2009), Massachusetts Medical Society[DOI]
- Henry G. Bone, "The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension", The Journal of Clinical Endocrinology & Metabolism, 98(11), pp.4483~4492 (2013), The Endocrine Society[DOI]
- Henry G. Bone, "Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass", The Journal of Clinical Endocrinology & Metabolism, 96(4), pp.972~980 (2011), The Endocrine Society[DOI]
- Paul D. Miller, "Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial", Bone, 43(2), pp.222~229 (2008), Elsevier BV[DOI]
- Benjamin Z. Leder, "Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up)", Bone, 98, pp.54~58 (2017), Elsevier BV[DOI]
- Helena Florez, "Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature", Seminars in Arthritis and Rheumatism, 49(2), pp.197~203 (2019), Elsevier BV[DOI]
- A. W. Popp, "Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics", Osteoporosis International, 27(5), pp.1917~1921 (2016), Springer Science and Business Media LLC[DOI]
- Olivier Lamy, "Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report", The Journal of Clinical Endocrinology & Metabolism, 102(2), pp.354~358 (2017), The Endocrine Society[DOI]
- B. Aubry-Rozier, "Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports", Osteoporosis International, 27(5), pp.1923~1925 (2016), Springer Science and Business Media LLC[DOI]
- Athanasios D Anastasilakis, "Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases", Journal of Bone and Mineral Research, 32(6), pp.1291~1296 (2017), Wiley[DOI]
- A. D. Anastasilakis, "Multiple clinical vertebral fractures following denosumab discontinuation", Osteoporosis International, 27(5), pp.1929~1930 (2016), Springer Science and Business Media LLC[DOI]
- Steven R Cummings, "Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension", Journal of Bone and Mineral Research, 33(2), pp.190~198 (2018), Wiley[DOI]
- M. R. McClung, "Observations following discontinuation of long-term denosumab therapy", Osteoporosis International, 28(5), pp.1723~1732 (2017), Springer Science and Business Media LLC[DOI]
- Judith Everts‐Graber, "A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains", Journal of Bone and Mineral Research, 35(7), pp.1207~1215 (2020), Wiley[DOI]
- T. Lehmann, "Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures", Osteoporosis International, 28(10), pp.3067~3068 (2017), Springer Science and Business Media LLC[DOI]
- Ian R. Reid, "Bone Loss After Denosumab: Only Partial Protection with Zoledronate", Calcified Tissue International, 101(4), pp.371~374 (2017), Springer Science and Business Media LLC[DOI]
- Anastasilakis AD, "Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial", J Bone Miner Res, 34, pp.2220~2228 (2019)[DOI]
- N. Freemantle, "Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women", Osteoporosis International, 23(1), pp.317~326 (2012), Springer Science and Business Media LLC[DOI]
- Anne M. Horne, "Bone Loss After Romosozumab", Denosumab: Effects of Bisphosphonates, 2018, pp.103(1), 55~61[DOI]